Paper Details

  1. Home
  2. Paper Details

Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.

Author: WeissLee R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Clarithromycin, levofloxacin, and cefuroxime axetil are all effective and well-tolerated treatments for acute bacterial exacerbations of chronic bronchitis (ABECB). While clarithromycin appears to be slightly more effective and better tolerated, the differences between the three treatments are not significant.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In the absence of a confirmed pathogen, empiric antimicrobial treatment of patients with acute exacerbations of chronic bronchitis and acute bacterial exacerbations of chronic bronchitis (ABECB) is accepted as standard practice and recommended in treatment guidelines. OBJECTIVE: This st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0149-2918(02)80045-5

データ提供：米国国立医学図書館（NLM）

Treating Chronic Bronchitis Exacerbations: Clarithromycin, Levofloxacin, and Cefuroxime Axetil

Acute bacterial exacerbations of chronic bronchitis (ABECB) are like a sandstorm sweeping across the lungs, causing discomfort and difficulty breathing. This study compares the efficacy and tolerability of three commonly used antibiotic regimens in treating ABECB: clarithromycin, levofloxacin, and cefuroxime axetil. The researchers conducted a randomized, open-label study to evaluate these antibiotics, each administered for 10 days.

Effective Antibiotics for ABECB

All three antibiotics showed high rates of clinical efficacy and tolerability, with a significant percentage of patients experiencing clinical cure or improvement. The researchers found that clarithromycin, levofloxacin, and cefuroxime axetil were all effective in clearing the sandstorm in the lungs and improving the patients' respiratory health.

Navigating the Sandstorm of ABECB

This study provides valuable insights into the treatment of ABECB. It highlights the effectiveness of these antibiotics and emphasizes the importance of personalized treatment based on individual needs and risk factors. By carefully selecting the right antibiotic, patients can effectively manage their ABECB and breathe easier.

Dr. Camel's Conclusion

This research provides a helpful guide for navigating the sandstorm of ABECB, offering insights into the effectiveness of clarithromycin, levofloxacin, and cefuroxime axetil. Armed with this knowledge, healthcare professionals can provide optimal care for patients suffering from this respiratory condition.

Date :
  1. Date Completed 2003-02-11
  2. Date Revised 2019-09-22
Further Info :

Pubmed ID

12380633

DOI: Digital Object Identifier

10.1016/s0149-2918(02)80045-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.